Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Uniqure N.V. (QURE)

Uniqure N.V. (QURE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,459,501
  • Shares Outstanding, K 62,292
  • Annual Sales, $ 27,120 K
  • Annual Income, $ -239,560 K
  • EBIT $ -180 M
  • EBITDA $ -167 M
  • 60-Month Beta 0.66
  • Price/Sales 83.85
  • Price/Cash Flow N/A
  • Price/Book 5.22

Options Overview Details

View History
  • Implied Volatility 281.44% (-8.16%)
  • Historical Volatility 94.02%
  • IV Percentile 98%
  • IV Rank 91.45%
  • IV High 302.43% on 02/17/26
  • IV Low 56.99% on 03/10/25
  • Expected Move (DTE 29) 12.67 (51.91%)
  • Put/Call Vol Ratio 0.81
  • Today's Volume 3,942
  • Volume Avg (30-Day) 6,275
  • Put/Call OI Ratio 0.22
  • Today's Open Interest 189,452
  • Open Int (30-Day) 152,923
  • Expected Range 11.74 to 37.07

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 14 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.93
  • Number of Estimates 5
  • High Estimate -0.75
  • Low Estimate -1.05
  • Prior Year -1.50
  • Growth Rate Est. (year over year) +38.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
20.17 +20.97%
on 02/13/26
28.48 -14.33%
on 02/03/26
+1.56 (+6.83%)
since 01/16/26
3-Month
19.29 +26.49%
on 12/15/25
29.99 -18.64%
on 11/24/25
-3.55 (-12.70%)
since 11/19/25
52-Week
7.76 +214.43%
on 04/09/25
71.50 -65.87%
on 10/28/25
+10.99 (+81.95%)
since 02/19/25

Most Recent Stories

More News
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in uniQure N.V. of Class Action Lawsuit and Upcoming Deadlines - QURE

NEW YORK , Feb. 19, 2026 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against uniQure N.V. ("uniQure" or the "Company") (NASDAQ: QURE). Such investors are...

QURE : 24.40 (+4.14%)
The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of April 13, 2026 in uniQure Lawsuit - QURE

NEW YORK , Feb. 19, 2026 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of uniQure N.V. (NASDAQ: QURE).

QURE : 24.40 (+4.14%)
NASDAQ: QURE: Kessler Topaz Meltzer & Check, LLP Files a Securities Fraud Class Action Lawsuit Against uniQure N.V.

Did you buy QURE ordinary shares between September 24, 2025, and October 31, 2025?

QURE : 24.40 (+4.14%)
uniQure N.V. Sued for Securities Law Violations - Contact Levi & Korsinsky Before April 13, 2026 to Discuss Your Rights - QURE

NEW YORK , Feb. 18, 2026 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in uniQure N.V. ("uniQure" or the "Company") (NASDAQ: QURE) of a class action securities lawsuit.

QURE : 24.40 (+4.14%)
QURE Investors Have Opportunity to Lead uniQure N.V. Securities Fraud Lawsuit

NEW YORK , Feb. 17, 2026 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of ordinary shares of uniQure N.V. (NASDAQ: QURE)...

QURE : 24.40 (+4.14%)
uniQure N.V. Securities Fraud Class Action Result of FDA Approval Delay and 49% Stock Decline - Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC

NEW YORK and NEW ORLEANS , Feb. 13, 2026 /PRNewswire/ -- Kahn Swick & Foti , LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors with substantial...

QURE : 24.40 (+4.14%)
QURE Stockholder Alert: Robbins LLP Reminds Investors of the Class Action Against uniQure N.V.

SAN DIEGO , Feb. 13, 2026 /PRNewswire/ -- Robbins LLP  reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired uniQure N.V. (NASDAQ:...

QURE : 24.40 (+4.14%)
QURE Investors Have Opportunity to Lead uniQure N.V. Securities Fraud Lawsuit

NEW YORK , Feb. 13, 2026 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of ordinary shares of uniQure N.V. (NASDAQ: QURE)...

QURE : 24.40 (+4.14%)
uniQure N.V. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - QURE

 LOS ANGELES , Feb. 13, 2026 /PRNewswire/ -- The DJS Law Group  reminds investors of a class action lawsuit against  uniQure N.V. ("uniQure " or "the Company") (NASDAQ: QURE ) for violations...

QURE : 24.40 (+4.14%)
QURE Investors Have Opportunity to Lead uniQure N.V. Securities Fraud Lawsuit with the Schall Law Firm

LOS ANGELES , Feb. 13, 2026 /PRNewswire/ -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against uniQure N.V. ("uniQure"...

QURE : 24.40 (+4.14%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 32% Sell with a Weakest short term outlook on maintaining the current direction.

Relative Strength just crossed above 50%. The market is indicating support for a bullish trend.

See More Share

Business Summary

UNIQURE B.V. is involved in developing gene therapy for patients of genetic or acquired diseases. It offers Glybera for the treatment of lipoprotein lipase deficiency, an orphan metabolic disease. The company's product pipeline includes which are in clinical trials are additional adeno-associated virus...

See More

Key Turning Points

3rd Resistance Point 26.91
2nd Resistance Point 25.78
1st Resistance Point 25.09
Last Price 24.40
1st Support Level 23.27
2nd Support Level 22.14
3rd Support Level 21.45

See More

52-Week High 71.50
Fibonacci 61.8% 47.15
Fibonacci 50% 39.63
Fibonacci 38.2% 32.11
Last Price 24.40
52-Week Low 7.76

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar